Lataa...
Efficacy and safety of rituximab biosimilar in refractory lupus
AIMS: To characterise patients with refractory SLE receiving rituximab biosimilar (CT-P10) and to explore short-term efficacy and safety associated with rituximab biosimilar use. METHODS: We retrospectively analysed data from the medical records of patients with refractory SLE who received CT-P10 in...
Tallennettuna:
| Julkaisussa: | Lupus Sci Med |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7607610/ https://ncbi.nlm.nih.gov/pubmed/33139454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2020-000442 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|